Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 250

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer

Open access
Morel, Katherine L., Sheahan, Anjali V., Burkhart, Deborah L., Baca, Sylvan C., Boufaied, Nadia, Liu, Yin, Qiu, Xintao, Cañadas, Israel, Roehle, Kevin, Heckler, Max, Calagua, Carla, Ye, Huihui, Pantelidou, Constantia, Galbo, Phillip, Panja, Sukanya, Mitrofanova, Antonina, Wilkinson, Scott, Whitlock, Nichelle C., Trostel, Shana Y., Hamid, Anis A., Kibel, Adam S., Barbie, David A., Choudhury, Atish D., Pomerantz, Mark M., Sweeney, Christopher J., Long, Henry W., Einstein, David J., Shapiro, Geoffrey I., Dougan, Stephanie K., Sowalsky, Adam G., He, Housheng Hansen, Freedman, Matthew L., Balk, Steven P., Loda, Massimo, Labbé, David P., Olson, Brian M., Ellis, Leigh · 2021 · Nature Cancer

Abstract

Prostate cancers are considered to be immunologically ‘cold’ tumors given the very few patients who respond to checkpoint inhibitor (CPI) therapy. Recently, enrichment of interferon-stimulated genes (ISGs) predicted a favorable response to CPI across various disease sites. The enhancer of zeste homolog-2 (EZH2) is overexpressed in prostate cancer and known to negatively regulate ISGs. In the present study, we demonstrate that EZH2 inhibition in prostate cancer models activates a double-stranded RNA–STING–ISG stress response upregulating genes involved in antigen presentation, Th1 chemokine signaling and interferon response, including programmed cell death protein 1 (PD-L1) that is dependent on STING activation. EZH2 inhibition substantially increased intratumoral trafficking of activated CD8+ T cells and increased M1 tumor-associated macrophages, overall reversing resistance to PD-1 CPI. Our study identifies EZH2 as a potent inhibitor of antitumor immunity and responsiveness to CPI. These data suggest EZH2 inhibition as a therapeutic direction to enhance prostate cancer response to PD-1 CPI. Ellis and colleagues show that combination of EZH2 inhibition and anti-PD-1 can increase antitumor immune responses in typically ‘immune cold’ prostate cancer, by increasing EZH2-regulated dsRNA–STING–ISG response signaling.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s43018-021-00185-w

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 250

Metadata

Authors
Morel, K. L., Sheahan, A. V., Burkhart, D. L., Baca, S. C., Boufaied, N., Liu, Y., Qiu, X., Cañadas, I., Roehle, K., Heckler, M., Calagua, C., Ye, H., Pantelidou, C., Galbo, P., Panja, S., Mitrofanova, A., Wilkinson, S., Whitlock, N. C., Trostel, S. Y., Hamid, A. A., Kibel, A. S., Barbie, D. A., Choudhury, A. D., Pomerantz, M. M., Sweeney, C. J., Long, H. W., Einstein, D. J., Shapiro, G. I., Dougan, S. K., Sowalsky, A. G., He, H. H., Freedman, M. L., Balk, S. P., Loda, M., Labbé, D. P., Olson, B. M., & Ellis, L.
Venue
Nature Cancer
Published
2021-03-22
Volume
2
Issue
4
Pages
444-456
ISSN
2662-1347 (ISSN-L)
OpenAlex
W3138735531
Cited by
250
References
22
FWCI
13.29
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. https://app.cochat.ai/papers/10.1038/s43018-021-00185-w
The paper
Morel, K. L., Sheahan, A. V., Burkhart, D. L., Baca, S. C., Boufaied, N., Liu, Y., Qiu, X., Cañadas, I., Roehle, K., Heckler, M., Calagua, C., Ye, H., Pantelidou, C., Galbo, P., Panja, S., Mitrofanova, A., Wilkinson, S., Whitlock, N. C., Trostel, S. Y., . . . Ellis, L. (2021). EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nature Cancer. https://doi.org/10.1038/s43018-021-00185-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.